Nordea Investment Management AB Has $796.03 Million Stock Holdings in Amgen Inc. $AMGN

Nordea Investment Management AB raised its stake in Amgen Inc. (NASDAQ:AMGN) by 8.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,851,938 shares of the medical research company’s stock after buying an additional 218,789 shares during the quarter. Amgen accounts for about 0.7% of Nordea Investment Management AB’s portfolio, making the stock its 25th largest position. Nordea Investment Management AB owned approximately 0.53% of Amgen worth $796,033,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Empirical Asset Management LLC lifted its stake in Amgen by 288.1% in the second quarter. Empirical Asset Management LLC now owns 4,273 shares of the medical research company’s stock valued at $1,193,000 after buying an additional 3,172 shares during the period. Consilio Wealth Advisors LLC increased its holdings in shares of Amgen by 9.6% in the second quarter. Consilio Wealth Advisors LLC now owns 801 shares of the medical research company’s stock worth $222,000 after acquiring an additional 70 shares in the last quarter. S Bank Fund Management Ltd bought a new stake in shares of Amgen in the second quarter worth about $1,017,000. Aire Advisors LLC increased its holdings in shares of Amgen by 4.0% in the second quarter. Aire Advisors LLC now owns 13,813 shares of the medical research company’s stock worth $3,857,000 after acquiring an additional 529 shares in the last quarter. Finally, Evernest Financial Advisors LLC increased its holdings in shares of Amgen by 10.6% in the second quarter. Evernest Financial Advisors LLC now owns 3,319 shares of the medical research company’s stock worth $927,000 after acquiring an additional 319 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on AMGN. Bank of America increased their price objective on Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a report on Friday, September 26th. Piper Sandler raised their price objective on Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a research report on Monday, August 25th. UBS Group dropped their price target on Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a report on Wednesday, August 6th. Citigroup lifted their price target on Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a report on Wednesday, September 24th. Finally, Morgan Stanley raised their price objective on Amgen from $330.00 to $333.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Seven research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $305.50.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the business’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president owned 7,209 shares in the company, valued at $2,141,000.91. The trade was a 14.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.76% of the stock is currently owned by corporate insiders.

Amgen Stock Performance

Amgen stock opened at $295.81 on Friday. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $335.88. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. The business’s 50-day moving average price is $286.93 and its two-hundred day moving average price is $287.33. The stock has a market cap of $159.25 billion, a PE ratio of 24.19, a P/E/G ratio of 2.63 and a beta of 0.49.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm had revenue of $9.18 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the previous year, the business posted $4.97 earnings per share. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date was Friday, August 22nd. Amgen’s payout ratio is currently 77.84%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.